Antisense therapies for FSHD, meaning AOs or RNAi drugs that target DUX4 mRNA, are the furthest along in preclinical development compared to other oligonucleotide approaches. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.